Biotech Investment News: AstraZeneca’s 10-Year Deal Overview & 2025 Update (2015–2025)
Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S...